SPRINTT and the involvement of stakeholders: strategy and structure
Tóm tắt
The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are, therefore, largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing segment of the older European population are not efficiently managed by the available healthcare services. In the context of an aging population, policy makers such as the European Commission and European Institutions, such as the European Medicines Agency (EMA), devote time and resources to study and accompany the need of the aging population. The EMA recognizes the importance of making sure that the needs of the Elderly are considered during development, approval, and use of new medicines, and, therefore, engages with healthcare professional organisations. The Sarcopenia and Physical Frailty in Older People: Multicomponent Intervention Strategies (SPRINTT) is the obvious result of these strategies. The present article describes the SPRINTT workpackage activities aimed at engaging the scientific discussion on the physical frailty and sarcopenia with the EMA as one of its interlocutor, acknowledging the need to collaborate on this topic to foster a productive dialogue.
Tài liệu tham khảo
Eurostat newsrelease. http://ec.europa.eu/eurostat/documents/2995521/7012459/3-29092015-AP-EN.pdf. Accessed 30 June 2016
EMA (2011) EMA geriatric medicines strategy. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/02/WC500102291.pdf. Accessed 29 June 2016
EMA (2013) Proposal for the development of a points to consider for baseline characterisation of frailty status. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144373.pdf. Accessed 29 June 2016
EMA (2015) Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199243.pdf. Accessed 29 June 2016
Concannon TW, Fuster M, Saunders T, Patel K, Wong JB, Leslie LK, Lau J (2014) A systematic review of stakeholder engagement in comparative effectiveness and patient-centered outcomes research. J Gen Intern Med 12:1692–1701. doi:10.1007/s11606-014-2878-x
de Boer P, Cesario A, Ignaszewski C (2015) Dialogue Platform Model. EU-Open. http://www.eu-open.it/the-dialogue-platform-model/?lang=en. Accessed 29 June 2016
Teunissen GJ, Visse MA, de Boer WI, Abma TA (2013) Structuring patient advocates’ appraisal and evaluation of health research and quality of care. J Participat Med 5:e16
MySPRINTT webpage Dialogue Platform. http://www.mysprintt.eu/dialogue-platform. Accessed 29 June 2016